Opdivo (nivolumab) is a prescription drug used to treat certain kinds of cancer. The drug comes as an intravenous (IV) infusion. How often you receive it depends on the cancer being treated.

Bristol Myers Squibb said a key European regulatory committee is backing a formulation of its blockbuster cancer drug Opdivo that can be injected under the skin.

NICE said Opdivo could only be used in patients whose cancers expressed the receptor PD-L1 – and even then BMS make the case for it to be paid for by the Cancer Drugs Fund until more robust data ...

Bristol-Myers Squibb must make the case for its Opdivo cancer immunotherapy to be included on England’s Cancer Drugs Fund in lung cancer, after NICE asked for more information on its ...

The committee based its decision on data showing the subcutaneous formulation of Opdivo was not inferior to the intravenous formulation.

The US Food and Drug Administration (FDA ... In October 2024, the FDA approved Opdivo for treating adults with resectable non ...

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...